In this study, subjects with spontaneous or tuberous sclerosis complex associated
lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such
as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better
evaluate disease activity in LAM subjects both before and after the initiation of mTOR
inhibitor therapy will be enrolled. The procedure for each scan will be similar, involving
one administration of the novel tracer C11-glutamine followed by a whole body PET/CT scan.